| Laura Michelle Levin Jones, AUD | |
|
2115 Wisconsin Ave Nw Ste 202, Washington, DC 20007-2265 | |
| (202) 944-5300 | |
| (877) 754-5490 |
| Full Name | Laura Michelle Levin Jones |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 6 Years |
| Location | 2115 Wisconsin Ave Nw Ste 202, Washington, District Of Columbia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659865921 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 2201001700 (Virginia) | Secondary |
| 231H00000X | Audiologist | (* (Not Available)) | Secondary |
| 231H00000X | Audiologist | AUD000195 (District Of Columbia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mgmc Llc | 9537073119 | 412 |
News Archive
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, today announced that it has been granted European Medicines Agency (EMA) approval to market Colobreathe dry powder colistimethate sodium for inhalation for treating cystic fibrosis patients aged 6 years and older with chronic lung infection caused by P. aeruginosa.
In a new study, researchers at Columbia University Medical Center demonstrated the significance of central corneal thickness (CCT) on the clinical management of patients with glaucoma and those suspected to have glaucoma.
Researchers at the Texas A&M Health Science Center Institute of Biosciences and Technology, and the University of Edinburgh have uncovered how a bacterial pathogen interacts with the blood coagulation protein fibrinogen to cause methicillin-resistant Staphylococcus aureus (MRSA) infections, a finding that could aid in developing therapeutics against the potentially deadly disease.
"At a time when many countries are seeing their HIV infection rates level off or decline," health officials in the Philippines "have seen an unexpected surge in cases in the past several years, with a more than five-fold increase between 2007 and 2011, with 2,349 new cases last year," the Wall Street Journal's "Southeast Asia Real Time" blog reports, noting, "The total number of cases as of April 2012 is 9,396, compared to just 3,061 in 2007."
Genentech and XOMA have announced preliminary 30-month (120 weeks) results from an open-label study evaluating the safety and efficacy of long-term continuous treatment with RAPTIVA® (efalizumab) in adults with moderate-to-severe chronic plaque psoriasis.
› Verified 5 days ago
| Provider Name | Mgmc Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1891797148 PECOS PAC ID: 9537073119 Enrollment ID: O20031220000056 |
News Archive
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, today announced that it has been granted European Medicines Agency (EMA) approval to market Colobreathe dry powder colistimethate sodium for inhalation for treating cystic fibrosis patients aged 6 years and older with chronic lung infection caused by P. aeruginosa.
In a new study, researchers at Columbia University Medical Center demonstrated the significance of central corneal thickness (CCT) on the clinical management of patients with glaucoma and those suspected to have glaucoma.
Researchers at the Texas A&M Health Science Center Institute of Biosciences and Technology, and the University of Edinburgh have uncovered how a bacterial pathogen interacts with the blood coagulation protein fibrinogen to cause methicillin-resistant Staphylococcus aureus (MRSA) infections, a finding that could aid in developing therapeutics against the potentially deadly disease.
"At a time when many countries are seeing their HIV infection rates level off or decline," health officials in the Philippines "have seen an unexpected surge in cases in the past several years, with a more than five-fold increase between 2007 and 2011, with 2,349 new cases last year," the Wall Street Journal's "Southeast Asia Real Time" blog reports, noting, "The total number of cases as of April 2012 is 9,396, compared to just 3,061 in 2007."
Genentech and XOMA have announced preliminary 30-month (120 weeks) results from an open-label study evaluating the safety and efficacy of long-term continuous treatment with RAPTIVA® (efalizumab) in adults with moderate-to-severe chronic plaque psoriasis.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Laura Michelle Levin Jones, AUD 3800 Reservoir Rd Nw Fl 1, Washington, DC 20007-2113 Ph: () - | Laura Michelle Levin Jones, AUD 2115 Wisconsin Ave Nw Ste 202, Washington, DC 20007-2265 Ph: (202) 944-5300 |
News Archive
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, today announced that it has been granted European Medicines Agency (EMA) approval to market Colobreathe dry powder colistimethate sodium for inhalation for treating cystic fibrosis patients aged 6 years and older with chronic lung infection caused by P. aeruginosa.
In a new study, researchers at Columbia University Medical Center demonstrated the significance of central corneal thickness (CCT) on the clinical management of patients with glaucoma and those suspected to have glaucoma.
Researchers at the Texas A&M Health Science Center Institute of Biosciences and Technology, and the University of Edinburgh have uncovered how a bacterial pathogen interacts with the blood coagulation protein fibrinogen to cause methicillin-resistant Staphylococcus aureus (MRSA) infections, a finding that could aid in developing therapeutics against the potentially deadly disease.
"At a time when many countries are seeing their HIV infection rates level off or decline," health officials in the Philippines "have seen an unexpected surge in cases in the past several years, with a more than five-fold increase between 2007 and 2011, with 2,349 new cases last year," the Wall Street Journal's "Southeast Asia Real Time" blog reports, noting, "The total number of cases as of April 2012 is 9,396, compared to just 3,061 in 2007."
Genentech and XOMA have announced preliminary 30-month (120 weeks) results from an open-label study evaluating the safety and efficacy of long-term continuous treatment with RAPTIVA® (efalizumab) in adults with moderate-to-severe chronic plaque psoriasis.
› Verified 5 days ago
Sheela L Stuart, PHD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-884-5600 | |
Karen Tal Woolman, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-476-5627 | |
Mrs. Elise Ney, M.A, CCC-A Audiologist Medicare: Accepting Medicare Assignments Practice Location: 4910 Massachusetts Ave Nw, Ste 29, Washington, DC 20016 Phone: 202-362-4300 | |
Ashley King, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 2300 M St Nw, Washington, DC 20037 Phone: 410-991-4749 | |
Dr. Claire Bernstein, PH.D Audiologist Medicare: Not Enrolled in Medicare Practice Location: 800 Florida Ave Ne, Washington, DC 20002 Phone: 301-509-0722 | |
Hearing 4life Inc Audiologist Medicare: Not Enrolled in Medicare Practice Location: 3301 New Mexico Ave Nw Ste 125, Washington, DC 20016 Phone: 202-621-6374 | |
Kelsey Ann Ambrose, Audiologist Medicare: Not Enrolled in Medicare Practice Location: 2300 M St Nw Fl 4, Washington, DC 20037 Phone: 202-741-3275 |